The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.

Creative Commons License

Aktepe O. H., GÜner G., GÜven D. C., Şahİn T. K., ArdiÇ F. S., YÜce D., ...More

Turkish journal of medical sciences, vol.51, pp.757-765, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 51
  • Publication Date: 2021
  • Doi Number: 10.3906/sag-2009-75
  • Journal Name: Turkish journal of medical sciences
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.757-765
  • Keywords: NLR, PLR, metastatic renal cell carcinoma, prognosis, tyrosine kinase inhibitors, PRETREATMENT NEUTROPHIL, PROGNOSTIC VALUE, POOR-PROGNOSIS, CANCER, INFLAMMATION, INFILTRATION, ASSOCIATION, EXPRESSION, COHORT, GRADE
  • Hacettepe University Affiliated: Yes

Abstract

Background/aim: The prognostic values of systemic inflammatory markers, neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR) on overall survival (OS) of metastatic renal cell carcinoma patients (mRCC) treated with tyrosine kinase inhibitors (TKI) remain unclear. Thus, the present study aimed to investigate the prognostic impact of these markers on OS of mRCC patients.